STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1

Cancer Sci. 2005 Feb;96(2):116-9. doi: 10.1111/j.1349-7006.2005.00018.x.

Abstract

The gastrointestinal stromal tumor cell line, GIST-T1, has a heterogenic 57-base pair deletion in exon 11 of the c-kit mutation, and the c-KIT protein in the GIST-T1 cells constitutively activated. We report that STI571 (Glivec; Novartis, Basel, Switzerland), a specific inhibitor of c-KIT, inhibits the clustering of c-KIT at the cell membrane of the GIST-T1 cells. Furthermore, STI571 prevents the interaction between c-KIT and the molecular chaperone, heat shock protein 90 (Hsp90). Geldanamycin, an inhibitor of Hsp90, also prevents interaction between c-KIT and Hsp90, and inhibits tyrosine phosphorylation of c-KIT. Our results indicate that c-KIT molecules are assembled on the cell surface of the GIST-T1 cells, and that the interaction between c-KIT and Hsp90 plays an important role in c-KIT activation.

MeSH terms

  • Benzamides
  • Benzoquinones
  • Cell Line, Tumor
  • Cell Membrane / metabolism
  • Cell Survival / drug effects
  • Drug Interactions
  • Gastrointestinal Stromal Tumors
  • HSP90 Heat-Shock Proteins / metabolism*
  • Humans
  • Imatinib Mesylate
  • Lactams, Macrocyclic
  • Phosphorylation
  • Piperazines / pharmacology*
  • Proto-Oncogene Proteins c-kit / metabolism*
  • Pyrimidines / pharmacology*
  • Quinones / pharmacology

Substances

  • Benzamides
  • Benzoquinones
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • Piperazines
  • Pyrimidines
  • Quinones
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit
  • geldanamycin